keyword
MENU ▼
Read by QxMD icon Read
search

The Lancet Oncology

keyword
https://www.readbyqxmd.com/read/29228640/comparison-of-primary-endpoints-between-publications-registries-and-protocols-of-phase-iii-cancer-clinical-trials
#1
Fei Liang, Xinmei Guo, Sheng Zhang, Hongxi Xue, Qiang Chen, Xichun Hu
Background: Decisions by leading journals to require trial registration and to make protocols of phase III randomized clinical trials (RCTs) publicly accessible were landmark events in clinical trial reporting. Materials and Methods: We identified phase III cancer RCTs published between 2013 and 2015 in New England Journal of Medicine (NEJM), The Lancet, The lancet Oncology, JAMA and Journal of Clinical Oncology (JCO). Results: We identified 345 reports of phase III RCTs of which 217 (62...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29213225/role-of-blue-dye-for-sentinel-lymph-node-detection-in-early-endometrial-cancer
#2
Stefano Restaino, Carlo Ronsini, Angelo Finelli, Emanuele Perrone, Giovanni Scambia, Francesco Fanfani
Background: Sentinel Lymphonode analysis has become a barely new and innovative way to treat early stages of endometrial cancer (Ballester et al., Lancet Oncol 469-476, 2011; Buda et al., Ann Surg Oncol 2975-81, 2016). Indocyanine green cervical injection is considered gold standard for mapping nodes' drainage. Blue dye is used as a valid alternative in many centers, due to the lower cost of execution. The objective of this video is to prove that methylene blue dye's cervical injection is a valid and "low-cost" method to obtain mapping of lymphatic drainage in patient with early endometrial cancer...
2017: Gynecological Surgery
https://www.readbyqxmd.com/read/29208427/clinical-decision-making-more-than-just-an-algorithm
#3
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
December 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29208398/future-cancer-research-priorities-in-the-usa-a-lancet-oncology-commission
#4
REVIEW
Elizabeth M Jaffee, Chi Van Dang, David B Agus, Brian M Alexander, Kenneth C Anderson, Alan Ashworth, Anna D Barker, Roshan Bastani, Sangeeta Bhatia, Jeffrey A Bluestone, Otis Brawley, Atul J Butte, Daniel G Coit, Nancy E Davidson, Mark Davis, Ronald A DePinho, Robert B Diasio, Giulio Draetta, A Lindsay Frazier, Andrew Futreal, Sam S Gambhir, Patricia A Ganz, Levi Garraway, Stanton Gerson, Sumit Gupta, James Heath, Ruth I Hoffman, Cliff Hudis, Chanita Hughes-Halbert, Ramy Ibrahim, Hossein Jadvar, Brian Kavanagh, Rick Kittles, Quynh-Thu Le, Scott M Lippman, David Mankoff, Elaine R Mardis, Deborah K Mayer, Kelly McMasters, Neal J Meropol, Beverly Mitchell, Peter Naredi, Dean Ornish, Timothy M Pawlik, Jeffrey Peppercorn, Martin G Pomper, Derek Raghavan, Christine Ritchie, Sally W Schwarz, Richard Sullivan, Richard Wahl, Jedd D Wolchok, Sandra L Wong, Alfred Yung
We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment...
November 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29208375/cancer-control-in-africa-infrastructure-not-philanthropy
#5
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
November 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29172995/pd-l1-blockade-with-avelumab-a-new-paradigm-for-treating-merkel-cell-carcinoma
#6
Savannah Barkdull, Isaac Brownell
Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer. Until recently, no durable treatment options were available for patients with advanced disease. As an immunogenic cancer, MCC was hypothesized to be a candidate for PD-L1/PD-1 targeted therapy. On March 23, 2017 the US Food and Drug Administration granted accelerated approval for avelumab, an anti-PD-L1 monoclonal antibody, for the treatment of metastatic MCC on the basis of the JAVELIN Merkel 200 trial. Here we examine the results and implications of this pivotal study, published in Lancet Oncology by Kaufman et al...
November 27, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29118233/hairy-cell-leukemia-version-2-2018-nccn-clinical-practice-guidelines-in-oncology
#7
William G Wierda, John C Byrd, Jeremy S Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, Asher Chanan-Khan, Steve E Coutre, Randall S Davis, Christopher D Fletcher, Brian Hill, Brad S Kahl, Manali Kamdar, Lawrence D Kaplan, Nadia Khan, Thomas J Kipps, Jeffrey Lancet, Shuo Ma, Sami Malek, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Andrew D Zelenetz, Mary A Dwyer, Hema Sundar
Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entity separate from HCLvariant (HCLv), which is associated with a more aggressive disease course and may not respond to standard HCL therapies. Somatic hypermutation in the IGHV gene is present in most patients with HCL. The BRAF V600E mutation has been reported in most patients with classic HCL but not in those with other B-cell leukemias or lymphomas...
November 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28971809/access-to-opioids-a-balance-of-harms
#8
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
October 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28884686/turning-taboos-into-action
#9
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
September 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28759366/calling-time-on-the-immunotherapy-gold-rush
#10
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
August 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28735121/survival-patterns-of-5750-stereotactic-radiosurgery-treated-patients-with-brain-metastasis-as-a-function-of-the-number-of-lesions
#11
Mir Amaan Ali, Brian R Hirshman, Bayard Wilson, Kate T Carroll, James A Proudfoot, Steven J Goetsch, John F Alksne, Kenneth Ott, Hitoshi Aiyama, Osamu Nagano, Bob S Carter, Gerald Fogarty, Angela Hong, Toru Serizawa, Masaaki Yamamoto, Clark C Chen
BACKGROUND: The number of brain metastases (BMs) plays an important role in the decision between stereotactic radiosurgery (SRS) and whole-brain radiation therapy. METHODS: We analyzed the survival of 5750 SRS-treated patients with BM as a function of BM number. Survival analyses were performed with Kaplan-Meier analysis as well as univariate and multivariate Cox proportional hazards models. RESULTS: Patients with BMs were first categorized as those with 1, 2-4, and 5-10 BMs based on the scheme proposed by Yamamoto et al...
November 2017: World Neurosurgery
https://www.readbyqxmd.com/read/28718304/the-role-of-surgery-in-low-grade-gliomas-do-timing-and-extent-of-resection-matter
#12
Hugues Duffau
Hugues Duffau is a Professor and Chairman of the Neurosurgery Department in the Montpellier University Medical Center and Head of the INSERM 1051 Team "plasticity of the central nervous system, human stem cells and glial tumors" at the Institute for Neurosciences of Montpellier (France). He is an expert in the awake cognitive neurosurgery of slow-growing brain tumors, such as low-grade gliomas, a routine which he has developed since 20 years. His fundamental approach is centered on the concepts of the brain connectomics and neuroplasticity, breaking with the traditional localizationist view of cerebral processing...
July 18, 2017: CNS Oncology
https://www.readbyqxmd.com/read/28687581/acute-myeloid-leukemia-version-3-2017-nccn-clinical-practice-guidelines-in-oncology
#13
Margaret R O'Donnell, Martin S Tallman, Camille N Abboud, Jessica K Altman, Frederick R Appelbaum, Daniel A Arber, Vijaya Bhatt, Dale Bixby, William Blum, Steven E Coutre, Marcos De Lima, Amir T Fathi, Melanie Fiorella, James M Foran, Steven D Gore, Aric C Hall, Patricia Kropf, Jeffrey Lancet, Lori J Maness, Guido Marcucci, Michael G Martin, Joseph O Moore, Rebecca Olin, Deniz Peker, Daniel A Pollyea, Keith Pratz, Farhad Ravandi, Paul J Shami, Richard M Stone, Stephen A Strickland, Eunice S Wang, Matthew Wieduwilt, Kristina Gregory, Ndiya Ogba
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.
July 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28677559/making-precision-oncology-the-standard-of-care
#14
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
July 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28593840/preventing-prevention-indian-politics-and-public-health-clash
#15
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
June 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28590426/down-s-syndrome-and-triple-negative-breast-cancer-a-rare-occurrence-of-distinctive-clinical-relationship
#16
Nandini Dey, Amy Krie, Jessica Klein, Kirstin Williams, Amanda McMillan, Rachel Elsey, Yuliang Sun, Casey Williams, Pradip De, Brian Leyland-Jones
Down's syndrome (DS), the most common genetic cause of significant intellectual disability in children and adults is caused by the trisomy of either all or a part of human chromosome 21 (HSA21). Patients with DS mostly suffer from characteristic tumor types. Although individual patients of DS are at a higher risk for acute leukemia and testicular cancers, other types of solid tumors including breast cancers are mostly uncommon and have significantly lower-than-expected age-adjusted incidence rates. Except for an increased risk of retinoblastomas, and lymphomas, the risk of developing solid tumors has been found to be lower in both children and adults, and breast cancer was found to be almost absent (Hasle H...
June 7, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28508770/romuald-w%C3%A4-g%C3%A5-owski-1876-1935-orthopaedic-surgeon-forgotten-pioneer-of-limb-saving-tumour-surgery
#17
Marek Durakiewicz, Mirosław Jabłoński, Aneta Zarębska
On May 16, 1914, The Lancet Journal published a paper by Romuald Węgłowski, a Polish-born professor of Moscow University, entitled "Malignant tumours of bones: a new method in conservative operative treatment." The idea of biological resection presented in the paper consisted in thermocoagulation of the apparently cancerous part of a bone with a jet of steam. According to the author, dead bone rid of live malignant cells reconstructed itself quickly, which helped to preserve the functionality of the organ without considerable limitations...
April 12, 2017: Ortopedia, Traumatologia, Rehabilitacja
https://www.readbyqxmd.com/read/28495275/cancer-risk-paradox-grand-plans-fall-short
#18
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
May 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28368245/colorectal-cancer-a-disease-of-the-young
#19
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
April 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28368244/preventable-cancer-off-limits-for-commonwealth-meeting
#20
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
April 2017: Lancet Oncology
keyword
keyword
86611
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"